Evidence map›Paper›PMID 29654976›Full record

ArticleBiochimica et biophysica acta. Proteins and proteomics

Mechanism of irreversible inhibition of Mycobacterium tuberculosis shikimate kinase by ilimaquinone.

Johayra Simithy, Ngolui Rene Fuanta, Judith V Hobrath, Anna Kochanowska-Karamyan, Mark T Hamann, Douglas C Goodwin, Angela I Calderón

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochimica et biophysica acta. Proteins and proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Inhibition of Shikimate Kinase from Methicillin-ResistantInternational journal of molecular sciences · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Johayra SimithyDepartment of Drug Discovery and Development, Harrison School of Pharmacy, 3306 Walker Building, Auburn University, Auburn, AL 36849, USA.
Ngolui Rene FuantaDepartment of Chemistry and Biochemistry, 179 Chemistry Building, Auburn University, Auburn, AL 36849, USA.
Judith V HobrathDrug Discovery Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom.
Anna Kochanowska-KaramyanDepartment of Pharmaceutical Sciences, Texas Tech University HSC, 1300 S. Coulter, Amarillo, TX 79106, USA.
Mark T HamannDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC 29425, USA.
Douglas C GoodwinDepartment of Chemistry and Biochemistry, 179 Chemistry Building, Auburn University, Auburn, AL 36849, USA.
Angela I CalderónDepartment of Drug Discovery and Development, Harrison School of Pharmacy, 3306 Walker Building, Auburn University, Auburn, AL 36849, USA. Electronic address: aic0001@auburn.edu.
Auburn University · USMedical University of South Carolina · USTexas Tech University · USUniversity of Dundee · GBWalker (United States) · US

Funding

Natural Product HCV Drugs from Rare Plant-Microbe InteractionsR01AT007318 · NCCIH · UNIVERSITY OF MISSISSIPPI · PI HAMANN, MARK T · 2012 to 2016
$1.6M
NCCIH NIH HHS R01 AT007318
6 · The paper itself

Abstract

Ilimaquinone (IQ), a marine sponge metabolite, has been considered as a potential therapeutic agent for various diseases due to its broad range of biological activities. We show that IQ irreversibly inactivates Mycobacterium tuberculosis shikimate kinase (MtSK) through covalent modification of the protein. Inactivation occurred with an apparent second-order rate constant of about 60 M

Indexed as

Adenosine TriphosphateAntitubercular AgentsBacterial ProteinsBinding SitesCatalytic DomainChromatography, LiquidKineticsL-Lactate DehydrogenaseMolecular Docking SimulationMycobacterium tuberculosisPhosphotransferases (Alcohol Group Acceptor)Protein BindingProtein Kinase InhibitorsQuinonesSesquiterpenesTandem Mass SpectrometryAdenosine TriphosphateAntitubercular AgentsBacterial ProteinsilimaquinoneL-Lactate DehydrogenasePhosphotransferases (Alcohol Group Acceptor)Protein Kinase InhibitorsQuinonesSesquiterpenesshikimate kinaseCovalent adductIlimaquinoneIrreversible inhibitorJump dilutionLiquid chromatography – mass spectrometryMolecular dockingMycobacterium tuberculosis shikimate kinaseShikimate‑3‑phosphateTandem MSTime-dependent inhibition

Identifiers

PMID29654976
PMCPMC11215815
OpenAlexW2796591151

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.